• How did you sleep last night?
    How did you sleep last night?
    Learn More      Sign Up     
  • Diabetes Research Enrolling Now!
    Diabetes Research Enrolling Now!
    Learn More      Sign Up     
  • Introducing Early Phase Trials
    Introducing Early Phase Trials
    Learn More      Sign Up     
  • Welcome to FICCR
    Welcome to FICCR

Welcome to Fleming Island Center for Clinical Research

Clinical trials move medicine forward. Sponsors, such as pharmaceutical companies, governments and foundations fund medical research. Patients who participate in clinical research receive many advantages including treatment at no cost, access to expertise and resources such as expensive tests. Research volunteers shape the future and can have fun while helping others and themselves.


As a premier clinical research organization, we have conducted more than 1,000 clinical trials over 20 years and have worldwide recognition for providing patients access to cutting edge medical research. If you have a medical issue and want a research solution, or if you are a healthy volunteer, come visit our center and learn more. One of our experts will be happy to evaluate you.

Shape the Future

Clinical research is a process that gives back. Volunteers generate information that improves future health care outcomes for everyone.                        

Find relief with new treatments

Volunteers join research to seek relief from affliction and to better understand their conditions with support from our caring team.

Programs Offer Resources or Pay

Study participants receive medical tests, services, counseling and treatment at no charge. These measures may be unavailable to the general public!

We do research in many areas

Diabetes Type II

Do You Have Type II Diabetes?
If you are at least 40 years old with type II diabetes and have established cardiovascular disease, you may be eligible to participate in a clinical research study being conducted by Fleming Island Center for Clinical Research Evaluating an investigational medication for diabetes.

Study participants will receive study-related medication and study-related medical evaluations at no charge. Compensation for time and travel is available for qualified participants. No insurance is required.
For additional information about the benefits and risks of the study please contact us:
or email


How did you sleep last night? 
If you are having trouble staying asleep at night, you may qualify for a research study of an investigational medication.


You may be eligible if:

· You are a male age 65 or older or a female age 55 or older

· You have trouble sleeping at least 3 times per week and for at least 3 months 
There are additional study requirements to qualify for participation. Qualified participants may receive study-related drug and medical exams. Qualified participants may receive compensation for time and travel. 
For more information:
(904) 621-0390
or email

View all active studies

Our Volunteers Love Us

Watch what they have to say about their research experience!

Phase I Research Terry's Experience
Phase I Research Debra's Experience
Phase 1 Research Joe's Experience

Sign Up

I'm interested in... (Scroll to select multiple)

Our Staff

View All

Karen Schuran

“I LOVE to shop!  I would shop all the time if I could!” says Karen Schuran, who earns her shopping money by being the Research Assistant and Lab Processor at Fleming Island Center for Clinical Research. Karen has been a member of our research family for 10 years and continues to be a valuable asset to the company.
She and her husband are celebrating their 25th Anniversary of marriage this month. They have two children, a daughter and a son. Karen is also “Grandma” to a cute, fuzzy bunny named Snoopy.
Karen’s favorite sport is football, which she has been learning more about so she can keep up with the men in the house. She also likes to watch game shows like Wheel of Fortune and Jeopardy, but Karen admits her real guilty pleasure is horror movies. “I absolutely LOVE horror movies, the scarier the better!”

Cindy Buda

"I do my part by managing the Fleming Island Office of Encore Research." On a daily basis I work as a Research Nurse Manager of our Fleming Island site supporting the Physician Investigators and staff in conducting clinical trials being carried out in our office. I am an original "Cheese Head" born in Green Bay Wisconsin and transplanted to Central Florida at the age of 10. I moved to Jacksonville for college and made Jacksonville my home. My greatest accomplishment is my four children. I enjoy family, cycling, travel and fishing.

Lisa Moore

Do you know Lisa Moore at Fleming Island Center for Clinical Research?  She has been a member of our research family for fourteen years, and surprisingly in addition to being an accomplished research coordinator, she is a home project expert.  She can often be seen gardening and renovating her old house! 

Lisa is the mother of two children and a French bulldog mix. She enjoys health and fitness, and is currently a CrossFit devotee who also likes to compete in 5k runs.  This allows her to burn off her favorite foods which include cheese fondue with veggies and Renna’s pizza.

During those rare, quieter moments, you might find her at home baking, crafting or crocheting with her dog Sparkles by her side. 

Lastest Blog Post:

Dropping the Hammer on Cholesterol

Heart disease currently accounts for 1 in 4 deaths in the United States.[1] However due to new research breakthroughs there are now treatments available that may finally give us the means to fight back against heart disease.  Historically heart disease has always been one of America’s most serious epidemics.  It has been a leading cause of death since the turn of the 20th Century.  Following World War II the National Heart, Lung and Blood Institute began a long term study known as the Framingham study to identify the cause of heart disease. 

The Framingham study is an enormous observational study in the town of Framingham, Massachusetts.  Researchers conducted physical examinations on participants every two years to study contributing factors to heart disease and are now on their 3rd generation of participants.  The Framingham study identified many of the currently known risk factors such as high blood pressure and high cholesterol.  Once high cholesterol was identified as a major risk factor, researchers began developing medications to combat cholesterol levels.  Some of our most exciting research at Encore Research Group is for these new cholesterol lowering medications such as PCSK9 inhibitors. 

PCSK9 inhibitors are an amazing class of drugs that allow us to lower LDL or “bad cholesterol” to previously unachievable levels.  These drugs are usually injectable and have many advantages over traditional statin drugs.  One such advantage is we are not seeing the muscle cramping associated with statin therapy. This is truly a breakthrough.

How low is too low? It is a question that researchers are actively addressing.  So far we have not seen complications or health risks as a result of very low LDL.  Some large studies that Encore Research has participated in will be releasing their results within the next year to more definitively answer this question. For now, there are many patients that have cholesterol levels that are difficult to budge but may respond to these new therapies.

Currently we are studying the effects of PCSK9 drugs in high risk populations such as diabetics. If you have high cholesterol levels that are not being adequately managed by your current medications, we may be able to help you get involved in a research study that may help get you back on track!  As many of our readers know, most research studies offer access to medication at no cost to patients. Call us to find out how you can get involved today!         

[1] CDC, NCHS. Underlying Cause of Death 1999-2013 on CDC WONDER Online Database, released 2015. Data are from the Multiple Cause of Death Files, 1999-2013, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Accessed Feb. 3, 2015.

View the full blog